Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01332253 · ClinicalTrials.gov registry record · Phase 3

Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy

A Phase 3 study of Tonsillectomy, sponsored by Cumberland Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
161
Enrollment target
6
Study locations

NCT01332253 is a Phase 3 study of Tonsillectomy that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 161 participants, below the 1,766-participant average among 6 other Tonsillectomy trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01332253, a Phase 3 study of Tonsillectomy, has completed, sponsored by Cumberland Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
161 participants
Enrollment target
6
Study locations

Study Summary

The hypothesis is that a single, pre-operative dose of intravenous ibuprofen will significantly reduce post-operative fentanyl use compared to placebo.

Conditions Studied

Interventions

  • OTHER Normal Saline
  • DRUG Intravenous ibuprofen

Study Locations (6)

Kentucky

  • Advanced ENT & Allergy - Louisville

New Jersey

  • University Hospital, University of Medicine and Dentistry NJ - Newark

North Carolina

  • Southeastern Clinical Research Associates - Charlotte

Pennsylvania

  • Children's Hospital of Pittsburgh - Pittsburgh

Tennessee

  • Comprehensive Pain Specialists - Hendersonville

Texas

  • Baylor College of Medicine/Texas Children's Hospital - Houston

Trial Details

FieldValue
Enrollment Target 161 participants
Start Date 2011-07
Est. Completion 2012-08
Phase Phase 3

Sponsor

Cumberland Pharmaceuticals

43 total trials

What the Registry Record Tells You About NCT01332253

The ClinicalTrials.gov registry entry for NCT01332253 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 161 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,766-participant average among 6 other Tonsillectomy trials with a reported enrollment target (91% lower). The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Tonsillectomy appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.

NCT01332253 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Kentucky, New Jersey, North Carolina.

Frequently Asked Questions

What is clinical trial NCT01332253 about?

NCT01332253 is a clinical study titled "Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy". The hypothesis is that a single, pre-operative dose of intravenous ibuprofen will significantly reduce post-operative fentanyl use compared to placebo.

What is the current status of trial NCT01332253?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 161 participants. The study started on 2011-07. Estimated completion is 2012-08.

What conditions does trial NCT01332253 study?

This clinical trial studies the following conditions: Tonsillectomy.

What interventions are being tested in trial NCT01332253?

The interventions under investigation include: Normal Saline (OTHER), Intravenous ibuprofen (DRUG).

Who is sponsoring clinical trial NCT01332253?

This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01332253 being conducted?

This trial has 6 study locations across Kentucky, New Jersey, North Carolina, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tonsillectomy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.